Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system

Current Treatment Options in Cardiovascular Medicine

Volumn 7, Issue 1, 2005, Pages 3-13

  Hedrich, Olaf ^b   Patten, Richard D ^b   DeNofrio, David ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANTACID AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CANDESARTAN; CAPTOPRIL; CLOPIDOGREL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; INTERFERON; IRBESARTAN; ITRACONAZOLE; KETOCONAZOLE; LISINOPRIL; LOSARTAN; MINERALOCORTICOID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; QUINAPRIL; RAMIPRIL; RENIN; SPIRONOLACTONE; TACROLIMUS; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; WARFARIN;

ABDOMINAL CRAMP; ADRENERGIC SYSTEM; AGRANULOCYTOSIS; ANGIONEUROTIC EDEMA; BETA ADRENERGIC RECEPTOR BLOCKING; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SUBSTITUTION; ENDOCRINE FUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FATIGUE; FEASIBILITY STUDY; FLU LIKE SYNDROME; GASTRITIS; GYNECOMASTIA; HEADACHE; HEALTH CARE COST; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LETHARGY; LIVER DYSFUNCTION; MENSTRUATION DISORDER; MORTALITY; NAUSEA; OUTCOMES RESEARCH; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TASTE DISORDER; TREATMENT OUTCOME; VOMITING;

EID: 21244503096     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-005-0001-7     Document Type: Review

References (58)

1. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2003.
2. Atlas SA, Case DB, Sealey JE, et al.: Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979, 1:274-280.
3. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334:1649-1654.
4. Burnier M, Brunner H: Angiotensin II receptor antagonists. Lancet 2000, 355:637-645.
5. Balcells E, Meng QC, Johnson WH Jr, et al.: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.
6. Ihara M, Urata H, Kinoshita A, et al.: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33:1399-1405.
7. Biollaz J, Brunner HR, Gavras I, et al.: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982, 4:966-972.
8. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993, 73:413-423.
9. Siragy HM, Carey RM: The subtype 2 (AT2) angiotensin receptor mediated renal production of nitric oxide in conscious rats. J Clin Invest 1997, 100:264-269.
10. Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 1999, 96:6506-6510.
11. Patten RD, Soman P: Prevention and reversal of LV remodeling with neurohormonal inhibitors. Curr Treat Options Cardiovasc Med 2004, 6:313-325.
12. Tamura T, Onodera T, Said S, Gerdes AM: Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. J Mol Cell Cardiol 1998, 30:2175-2181.
13. Beltrami CA, Finato N, Rocco M, et al.: The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995, 27:291-305.
14. Kawano H, Do YS, Kawano Y, et al.: Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130-1137.
15. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
16. Lombes M, Oblin ME, Gasc JM, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503-510.
17. Mizuno Y, Yoshimura M, Yasue H, et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72-77.
18. Yamamoto N, Yasue H, Mizuno Y, et al.: Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002, 39:958-962.
19. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
20. Diet F, Pratt RE, Berry GJ, et al.: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94:2756-2767.
21. Weiss D, Kools JJ, Taylor WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 3:448-454.
22. Nickenig G, Harrison DG: The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002, 105:530-536.
23. Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105:1605-1612.
24. Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999, 84:695-703.
25. Kranzhofer R, Schmidt J, Pfeiffer CAH, et al.: Angiotensin II induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000, 19:1623-1629.
26. Tummala PE, Chem XL, Sundell CL, et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999, 100:1223-1229.
27. Chen XL, Tummala PE, Olbrych MT, et al.: Angiotensin II induces monocyte chemoattractant protein-1 gene in rat vascular smooth muscle cells. Circ Res 1998, 83:952-959.
28. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al.: Inflammation and angiotensin II. Int J Biochem Cell Biol 2003, 35:881-900.
29. Nakamura S, Nakamura I, Ma L, et al.: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251-259.
30. Brown NJ, Vaughan DE: Prothrombotic effects of angiotensin. Adv Intern Med 2000, 45:419-429.
31. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995-1001.
32. Pfeffer MA, Greaves SC, Arnold JMO, et al.: Early vs. delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: the Healing and Early Afterload Reducing Therapy trial. Circulation 1997, 95:2643-2651.
33. Strawn WB, Chappell MC, Dean RH, et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101:1586-1593.
34. Pitt B: The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. Clin Cardiol 2000, 23:IV9-IV14.
35. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
36. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group [no authors listed]. N Engl J Med 1987, 316:1429-1435.
37. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293-302.
38. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:685-691.
39. Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS Study Group. Circulation 1999, 100:2312-2318.
40. Heart Failure Society of America: HFSA Practice Guidelines: Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction - Pharmacological Approaches. http://www.hfsa.org/pdf/lvsd_heart_failure.pdf. Accessed August 7, 2004.
41. Drug Topics Red Book. Edited by Cohen HE. Montvale, NJ: Thomson PDR, 2003.
42. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza Nell'infarto Miocardico [no authors listed]. Lancet 1994, 343:1115-1122.
43. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group [no authors listed]. Lancet 1995, 345:669-685.
44. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 327:669-677.
45. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [no authors listed]. Lancet 1993, 342:821-828.
46. Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670-1676.
47. American College of Cardiology Foundation and the American Heart Association, Inc.: ACC/AHA Practice Guidelines - Full Text: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. http://www.acc.org/clinical/guidelines/stemi/index.pdf. Accessed August 7, 2004.
48. Massie BM, Teerlink JR: Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined. Am J Med 2000, 109:431-433.
49. Al-Khadra AS, Salem DN, Rand WM, et al.: Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1998, 1:419-425.
50. Peterson JG, Topol EJ, Sapp SK, et al.: Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000, 109:371-377.
51. Pitt B, Segal R, Martinez FA, et al.: Randomized trial of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study (ELITE II). Lancet 2000, 355:1582-1587.
52. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (Val-HeFT). N Engl J Med 2001, 345:1667-1675.
53. Maggioni AP, Anand I, Gottlieb SO, et al.: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002, 40:1414-1421
54. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on morbidity and mortality in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
55. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
56. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709-717.
57. Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
58. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.